|
LONDON (AP) - Pharmaceutical company Shire PLC said Thursday that the U.S. Food and Drug Administration indicated that it may approve the company's Intuniv treatment for attention-deficit hyperactivity disorder for children.
The FDA has also requested additional information on the treatment, Shire — which also makes the attention deficit hyperactivity disorder drug Adderall — said in a statement.
Unlike some ADHD treatments, the company said, Intuniv — a nonstimulant — is not a controlled substance and does not have a known mechanism for potential abuse or dependence.
|